Pseudomonas vaccine - Berna Biotech
Alternative Names: AerugenLatest Information Update: 19 Jul 2006
At a glance
- Originator Berna Biotech
- Class Bacterial vaccines; Pseudomonas vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pseudomonal infections
Most Recent Events
- 18 Jul 2006 Discontinued - Phase-III for Pseudomonal infections in Europe (IM)
- 04 Aug 2005 Aerugen® has been licensed to Solvay Pharmaceuticals in the US, Canada, Latin America and other international markets
- 27 Jun 2005 Aerugen® has been licensed to CSL in Australia and New Zealand